Results 221 to 230 of about 470,131 (305)

Emerging Role of ctDNA Fragmentomics and Epigenetic Signatures in the Early Detection, Minimal Residual Disease Assessment, and Precision Monitoring of Renal Cell Carcinoma. [PDF]

J Cell Mol Med
Kamli H, Khan NU.
europepmc   +1 more source

Suppression of lung adenocarcinoma migration through organelle alkalization by human lactoferrin – albumin fusion

FEBS Open Bio, EarlyView.
This paper reveals how human lactoferrin–albumin fusion (hLF‐HSA) potently suppresses lung adenocarcinoma cell migration. hLF‐HSA upregulates NHE7, leading to Golgi alkalization, disruption of the Golgi secretome, downregulation of MMP1, and reversal of EMT. These findings suggest a novel Golgi‐targeting strategy to suppress cancer cell migration.
Hana Nopia, Masahiro Kimura, Daisuke Kurimoto, Atsushi Sato   +3 more
wiley   +1 more source

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia

Clinical Medicine Insights: Oncology, 2015
Jitsuda Sitthi-amorn, Betty Herrington, Gail Megason, Jeanette Pullen, Catherine Gordon, Shirley Hogan, Tejaswi Koganti, Chindo Hicks   +7 more
doaj  

Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study. [PDF]

Blood Res
Oh S, Park SS, Lee JY, Yoon JH, Lee SE, Kim HJ, Shin SH, Jeon YW, Yahng SA, Jung J, Ahn A, Kim M, Min CK.   +12 more
europepmc   +1 more source

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

FEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani, Eiman Y. Ibrahim, Rozalyn L. Rodwin, Leah M. Ferrucci, Kim Blenman, Maryam Lustberg, Barbara E. Ehrlich   +6 more
wiley   +1 more source

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma. [PDF]

Future Oncol
Gordan LN, Warner A, Heritage T, Ming A, Gupta-Werner N, Kaila S, Cortoos A.   +6 more
europepmc   +1 more source

Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer

FEBS Open Bio, EarlyView.
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo, Keisuke Okuno, Shuichi Watanabe, Sakiko Oba, Hiroyasu Kagawa, Masanori Tokunaga, Daisuke Ban, Yusuke Kinugasa   +7 more
wiley   +1 more source

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution. [PDF]

BMC Med
Liang JH, Wu YF, Pan SY, Du KX, Ji YL, Zhu LQ, Shen HR, Wu JZ, Yin H, Li Y, Wang L, Li JY, Xu W.   +12 more
europepmc   +1 more source

[Minimal residual disease].

Haematologica, 1992
P, Francia di Celle, R, Foà
openaire   +1 more source

YIPFα1A expression is regulated by multilayered molecular mechanisms

FEBS Open Bio, EarlyView.
YIPFα1A, a five‐pass Golgi protein, is regulated at multiple layers. (1) Rare‐codon enrichment drives translation‐coupled mRNA decay. (2) A proximal 3′‐UTR element stabilizes mRNA. (3) A distal 3′‐UTR element included by alternate poly(A) site usage represses translation, which can be overridden by the proximal 3′‐UTR element.
Tokio Takaji, Yurika Nakanishi, Nobuhiro Nakamura   +2 more
wiley   +1 more source